Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
multi-center, randomized, double-blind, parallel-group,placebo-controlled study to evaluate
the safety and tolerability, efficacy, and PK of 60 mg AD-35 administered QD during 6 months
of double-blind treatment followed by a second 6 months of open-label treatment to subjects
with mild to moderate AD.